Tightening Schlemm's canal reduces IOP

Article

Tensioning of Schlemm's canal may reduce intraocular pressure (IOP) in non-penetrating surgical treatment of open angle glaucoma (OAG), according to the results of a study conducted by Manfred Tetz and colleagues from Germany.

Tensioning of Schlemm's canal may reduce intraocular pressure (IOP) in non-penetrating surgical treatment of open angle glaucoma (OAG), according to the results of a study conducted by Manfred Tetz and colleagues from Germany.

During a multicentre clinical study at four European and six US outpatient surgical centres, Schlemm's canal was exposed by surgical dissection during viscocanalostomy of 92 eyes. A flexible microcannula was inserted and advanced along the circumference to viscodilate the canal. Then a 10-0 prolene suture was tied to the tip of the microcannula and retracted into the canal and the suture ends were tied to apply tension to the inner wall and the trabecular meshwork. In 33 patients, the trabecular meshwork distension was measured using high resolution ultrasound imaging and correlated to IOP at one, three and six months postoperatively.

Average preoperative IOP was recorded at 27.8 mmHg on 2.0 medications. Six months postoperatively, 19 eyes with low suture tension had an average IOP of 15.0 mmHg on 0.13 medications as compared with 14 eyes with high suture tension whose average IOP was 13.6 mmHg on 0.10 medications.

The authors concluded that there is a correlation between reduced postoperative IOP and increased tension and that by tensioning Schlemm's canal it may be possible to reduce IOP in non-penetrating surgical treatment of OAG.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.